liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Cellular ADMA: regulation and action.
VU Medisch Centrum, Amsterdam.
Georgetown University.
Uppsala universitet, Integrativ Fysiologi.
Georgetown University.
2009 (English)In: Pharmacological Research, ISSN 1043-6618, E-ISSN 1096-1186, Vol. 60, no 6, 448-460 p.Article, review/survey (Refereed) Published
Abstract [en]

Asymmetric (N(G),N(G)) dimethylarginine (ADMA) is present in plasma and cells. It can inhibit nitric oxide synthase (NOS) that generates nitric oxide (NO) and cationic amino acid transporters (CATs) that supply intracellular NOS with its substrate, l-arginine, from the plasma. Therefore, ADMA and its transport mechanisms are strategically placed to regulate endothelial function. This could have considerable clinical impact since endothelial dysfunction has been detected at the origin of hypertension and chronic kidney disease (CKD) in human subjects and may be a harbinger of large vessel disease and cardiovascular disease (CVD). Indeed, plasma levels of ADMA are increased in many studies of patients at risk for, or with overt CKD or CVD. However, the levels of ADMA measured in plasma of about 0.5micromol.l(-1) may be below those required to inhibit NOS whose substrate, l-arginine, is present in concentrations many fold above the Km for NOS. However, NOS activity may be partially inhibited by cellular ADMA. Therefore, the cellular production of ADMA by protein arginine methyltransferase (PRMT) and protein hydrolysis, its degradation by N(G),N(G)-dimethylarginine dimethylaminohydrolase (DDAH) and its transmembrane transport by CAT that determines intracellular levels of ADMA may also determine the state of activation of NOS. This is the focus of the review. It is concluded that cellular levels of ADMA can be 5- to 20-fold above those in plasma and in a range that could tonically inhibit NOS. The relative importance of PRMT, DDAH and CAT for determining the intracellular NOS substrate:inhibitor ratio (l-arginine:ADMA) may vary according to the pathophysiologic circumstance. An understanding of this important balance requires knowledge of these three processes that regulate the intracellular levels of ADMA and arginine.

Place, publisher, year, edition, pages
2009. Vol. 60, no 6, 448-460 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-99309DOI: 10.1016/j.phrs.2009.08.002PubMedID: 19682580OAI: diva2:657200
Available from: 2011-01-11 Created: 2013-10-15 Last updated: 2013-10-18

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Palm, Fredrik
In the same journal
Pharmacological Research
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 16 hits
ReferencesLink to record
Permanent link

Direct link